Provided by Tiger Trade Technology Pte. Ltd.

REMEGEN

78.900
-1.000-1.25%
Volume:3.17M
Turnover:250.29M
Market Cap:44.47B
PE:52.42
High:80.800
Open:79.800
Low:77.250
Close:79.900
52wk High:126.600
52wk Low:63.300
Shares:563.61M
HK Float Shares:208.58M
Volume Ratio:0.85
T/O Rate:1.52%
Dividend:- -
Dividend Rate:- -
EPS(LYR):1.505
ROE:45.33%
ROA:3.38%
PB:9.70
PE(LYR):52.42
PS:11.27

Loading ...

Hong Kong Market Rallies: Hang Seng Gains 1.57%, Biotech and Tech Sectors Lead Charge

Stock News
·
Jun 29

Hong Kong Market Midday Recap: Hang Seng Index Gains 2.12%, Reclaims 23,000 Level; Tech Index Up 3.68% with Broad-Based Gains

Deep News
·
Jun 29

Hong Kong Market Midday Update: Hang Seng Index Climbs 2.12%, Biotech and Pharma Stocks Surge

Stock News
·
Jun 29

Movement Alert|Remegen Rises 5.38% in Regular Trading, Lock-up Share Selling Restrictions and New Drug Approvals Drive Gains

Market Focus
·
Jun 29

Movement Alert|RemeGen Rises 5.31% in Regular Trading, HK Biotech Sector Extends Rebound as Lock-Up Share Selling Restrictions Ease Overhang Concerns

Market Focus
·
Jun 24

Movement Alert|RemeGen Rises 5.02% in Regular Trading, Sector Rebounds as Lock-up Expiry Selling Pressure Eased by Regulatory Restriction

Market Focus
·
Jun 23

Hong Kong Stocks Flat In Morning Trading

Dow Jones
·
Jun 23

HK Movers | Biotech Stocks Jump. InnoGen up over 17%; Alphamab, Hengrui Pharma, Laekna, Keymed Bio up Around 5%; Joinn, Remegen up About 4%

Tiger Newspress
·
Jun 23

Remegen to Release 193 Million Locked Shares on July 1

Stock News
·
Jun 22

Movement Alert|RemeGen Falls 5.33% in Regular Trading, HK Innovative Drug Sector Under Sustained Selling Pressure

Market Focus
·
Jun 22

RemeGen (SEHK:9995) Is Down 8.1% After Expanded Telitacicept Approvals in China Reshape Its Pipeline Narrative

Simply Wall St.
·
Jun 21

RemeGen (SEHK:9995) Stock Could Be 39% Below Fair Value After Telitacicept Approvals

Simply Wall St.
·
Jun 19

REMEGEN Announces Board Re-Elections, Including Chairman and CEO

Stock News
·
Jun 16

Movement Alert|RemeGen Falls 5.06% in Regular Trading, HK Innovative Drug Sector Under Sustained Selling Pressure

Market Focus
·
Jun 16

Innovative Drug Stocks See Broad Gains as Sector's Outbound Licensing Activity Remains Robust, Supported by Policy Tailwinds and Commercialization Progress

Stock News
·
Jun 12

Movement Alert|RemeGen Rises 5.38% in Regular Trading, Dual Indication Approval for Core Drug Telitacicept Continues to Boost Sentiment

Market Focus
·
Jun 12

RemeGen (SEHK:9995) Valuation Check After Recent Share Price Weakness And Multi Year Gains

Simply Wall St.
·
Jun 10

BUZZ-RemeGen Shanghai shares jump most in 10 weeks on China nod for new drug marketing

Reuters
·
Jun 09

New Drug from REMEGEN Gains Approval, Boosting A and H Share Prices; Pharmaceutical ETF Rebounds, Hong Kong Stock Connect Innovative Drug ETF Maintains Premium

Deep News
·
Jun 09

REMEGEN Shares Surge on Dual Indication Approvals for Telitacicept

Stock News
·
Jun 09